^
Association details:
| Biomarker: | BRAF wild-type |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Published date:
10/25/2022
Excerpt:
In RAS-wt and BRAF-wt patients not previously treated with EGFR antibodies, cetuximab and panitumumab are recommended as single agents...
Source:
Title:
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Excerpt:
...Overall Survival`Percentage of Participants With an Objective Response`Duration of Response`Time to Disease Progression`Time to Initial Objective Response`Resection Rate`Progression-free Survival (PFS) in Participants With Wild-type Rat Sarcoma Viral Oncogene Homolog (RAS)`Progression-free Survival (PFS) in Participants With Wild-type RAS / V-raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)`Overall Survival in Participants With Wild-type RAS`Overall Survival in Participants With Wild-type RAS / BRAF`Percentage of Participants With an Objective Response for Participants With Wild-type RAS`Percentage of Participants With an Objective Response for Participants With Wild-type RAS / BRAF`Number of Participants With Adverse Events (AEs)...
Trial ID:
Source:
Title:
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
Excerpt:
...RAS/BRAF wild-type status in solid biopsy confirmed prior to inclusion of the study, 5....
Trial ID:
More C2 evidence
Source:
Title:
Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients
Excerpt:
...- RAS and BRAF status wild-type of primary colorectal cancer or related metastasis, centrally assessed....
Trial ID:
Source:
Title:
FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer
Excerpt:
...- KRAS and BRAF wild-type status of primary colorectal cancer or related metastasis;...
Trial ID:
Source:
Title:
MONARCC: A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer.
Excerpt:
...BRAF wild type as assessed by the investigator's choice of testing laboratory. ...
Trial ID:
Source:
Title:
The purpose of this clinical research is to compare two different treatments to assess whether the use of a single chemotherapy (5-FU) in combination with panitumumab may provide better results in terms of safety and efficacy compared to treatment with two chemotherapy drugs (5 -fluorouracile and oxaliplatin) in combination with panitumumab as first-line therapy in elderly patients (aged =70 years) with cancer without mutations of RAS and BRAF. Lo scopo di questa ricerca clinica è confrontare due diversi trattamenti per valutare se l'utilizzo di un solo chemioterapico (5-fluorouracile) in associazione a panitumumab possa fornire risultati migliori in termini di tollerabilità ed efficacia rispetto ad un trattamento con due farmaci chemioterapici (5-fluorouracile e oxaliplatino) in associazione a panitumumab come terapia di prima linea nei pazienti anziani (età =70 anni) con neoplasia senza mutazioni dei geni RAS e BRAF.
Excerpt:
...ECOG PS 1 or 2 for patients aged 70 to 75 years; ECOG PS 0 or 1 for patients aged > 75 years.Life expectancy of at least 12 weeks.Previous adjuvant chemotherapy allowed only if with fluoropyrimidine monotherapy and more than 6 months elapsed between the end of adjuvant and first relapse.RAS and BRAF status wild-type of primary colorectal cancer or related metastasis, centrally assessed.Neutrophils =1.5 x 109/L, Platelets =100 x 109/L, Hgb =9 g/dl.Total bilirubin =1.5 time the upper-normal limits (UNL) of the normal values and ASAT (SGOT) and/or ALAT (SGPT) =2.5 x UNL (or <5 x UNL in case of liver metastases) alkaline phosphatase =2.5 x UNL (or <5 x UNL in case of liver metastases).Creatinine clearance =50 mL/min or serum creatinine =1.5 x UNL.Male subjects with female partners of childbearing potential must be willing to use adequate contraception as approved by the investigator (barrier contraceptive measure or oral contraception).Geriatric assessment by means of G8 screening and CRASH score. ...
Trial ID:
Less C2 evidence
Source:
Title:
Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study.
Published date:
05/26/2022
Excerpt:
...previously untreated RAS/BRAF wt mCRC pts, were randomized to a control arm (A) receiving FOLFIRI/PANI...At a median follow-up of 18 months (IQR: 10-26), median PFS OT was 12.6 months (95% CI: 9.0-16.1) in arm A and 17.6 months (95% CI: 7.5-27.8) in arm B with a 1 year PFSOT rate of 51.7% and 61.3%, respectively. ORR (arm A/B) was 64/56%....The primary endpoint of the study was met with the intermittent FOLFIRI-PANI strategy producing a long PFS...
Secondary therapy:
FOLFIRI
DOI:
10.1200/JCO.2022.40.16_suppl.3503
Trial ID:
